Literature DB >> 10738186

Multifocality in renal cell carcinoma: A bilateral event?

H Wunderlich1, A Schlichter, D Zermann, O Reichelt, H Kosmehl, J Schubert.   

Abstract

OBJECTIVES: The major disadvantage of nephron-sparing surgery for renal cell carcinoma is the risk of local recurrence. This is most likely a manifestation of undetected small additional tumors in the renal remnant. To define more clearly the incidence and nature of unilateral and bilateral multifocal tumors, an autopsy study was undertaken.
MATERIALS AND METHODS: In a series of 14,793 autopsies from 1985 to 1995, 260 renal cell carcinomas were found. In all cases of renal cell carcinoma a search for small renal lesions was performed in the apparently normal-appearing portion of the kidneys. Every kidney was serially and systematically cut (5 mm) to probe for intraparenchymal lesions.
RESULTS: Of the 260 renal cell carcinomas 36 cases (13.85%) had multifocal malignant and/or benign nodules. The number of the additional nodules ranged from 2 to 18. 12% of the malignant multifocal carcinomas were limited to the ipsilateral kidney and 88% were bilateral. The average size of the multifocal renal lesions was 8.7 x 9.0 x 9.5 (range 3-23) mm. Renal cell carcinomas with low stage and good grading have a higher incidence of multifocal nodules. No significant difference was found with regard to metastasized and nonmetastasized renal cell carcinomas. In 38.1% of all chromophilic renal cell carcinomas additional nodules were found.
CONCLUSIONS: Multifocality in renal cell carcinomas cannot be predicted reliably, although the papillary histological pattern, good grading and low staging seems to be associated with a higher incidence of multifocality. Nearly 90% of the multifocal nodules were bilateral. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  1999        PMID: 10738186     DOI: 10.1159/000030439

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  9 in total

Review 1.  Long-term management of bilateral, multifocal, recurrent renal carcinoma.

Authors:  Gennady Bratslavsky; W Marston Linehan
Journal:  Nat Rev Urol       Date:  2010-05       Impact factor: 14.432

Review 2.  The evolving role of partial nephrectomy in the management of renal cell carcinoma.

Authors:  Scott M Gilbert; Paul Russo; Mitchell C Benson; Carl A Olsson; James M McKiernan
Journal:  Curr Oncol Rep       Date:  2003-05       Impact factor: 5.075

3.  [Incidence and long-term prognosis of papillary renal cancer. Results of a retrospective multicenter study].

Authors:  S Waalkes; F C Roos; H Eggers; S Schumacher; M Janssen; G Wegener; J W Thüroff; R Hofmann; M Schrader; M A Kuczyk; A J Schrader
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

Review 4.  Repeat partial nephrectomy: surgical, functional and oncological outcomes.

Authors:  Brian Shuch; W Marston Linehan; Gennady Bratslavsky
Journal:  Curr Opin Urol       Date:  2011-09       Impact factor: 2.309

Review 5.  Nephron-sparing surgery for multifocal and hereditary renal tumors.

Authors:  Adam R Metwalli; William M Linehan
Journal:  Curr Opin Urol       Date:  2014-09       Impact factor: 2.309

6.  Incidence and long-term prognosis of papillary renal cell carcinoma.

Authors:  A J Schrader; S Rauer-Bruening; P J Olbert; A Hegele; J Rustemeier; N Timmesfeld; Z Varga; R Hofmann
Journal:  J Cancer Res Clin Oncol       Date:  2008-11-21       Impact factor: 4.553

7.  Renal cell carcinoma and prognostic factors predictive of survival.

Authors:  M Sorbellini; G Bratslavsky
Journal:  Ann Surg Oncol       Date:  2010-02       Impact factor: 5.344

8.  Decreasing the indications for radical nephrectomy: a study of multifocal renal cell carcinoma.

Authors:  Maximiliano Sorbellini; Gennady Bratslavsky
Journal:  Front Oncol       Date:  2012-08-06       Impact factor: 6.244

9.  Multifocal renal cell carcinoma: clinicopathologic features and outcomes for tumors </=4 cm.

Authors:  Paul L Crispen; Christine M Lohse; Michael L Blute
Journal:  Adv Urol       Date:  2008
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.